Cost-effectiveness of lutetium ((177)Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden

BACKGROUND: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a relatively rare and heterogenous group of tumors. Currently available treatment options for patients with progressive GEP-NETs include lutetium ((177)Lu) oxodotreotide ((177)Lu-Dotatate) and everolimus [as well as suniti...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmer, Jayne, Leeuwenkamp, Oscar R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642527/
https://www.ncbi.nlm.nih.gov/pubmed/33195647
http://dx.doi.org/10.12998/wjcc.v8.i20.4793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642527/
https://www.ncbi.nlm.nih.gov/pubmed/33195647
http://dx.doi.org/10.12998/wjcc.v8.i20.4793

Ejemplares similares